Improving short and medium term patient and graft survival rates for pediatric kidney transplant recipients over the past two decades has led to an increased focus on the study of late posttransplant complications. We review important papers over the past decade and highlight recent publications from 2004 to 2007 that address challenges to long-term outcomes in this patient group.
Introduction
Expected 1-year and 5-year kidney allograft survival rates surpassing 95 and 80%, respectively, are now commonly achieved in major pediatric centers [1] . Challenges to successful long-term outcomes in pediatric kidney transplant recipients include acute and chronic rejection, calcineurin inhibitor nephrotoxicity, and progressive renal injury, otherwise known as chronic allograft nephropathy (CAN) [2] [3] [4] [5] [6] . Newer immunosuppressive protocols include calcineurin inhibitor-sparing and steroid avoidance strategies in conjunction with powerful agents to prevent acute cellular rejection (ACR). The ultimate objective is to minimize the risk factors for CAN and to prolong allograft survival, while avoiding the adverse effects of corticosteroids.
Living donor kidney transplantation
A potential area of growth for pediatric kidney transplantation is to increase the rates of donation from living donors, including altruistic and anonymous donors. In North American children living donor kidney transplantation increased from 43% in the years between 1987 and 1991, to 52% in the years between 1987 and 2004 [7 ] . Long-term graft survival rates for pediatric patients transplanted since 1995 remain higher in recipients of living donor kidneys compared with those of deceased donor kidneys. Data from the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) show 5-year and 7-year graft survival rates for patients transplanted between 1995 and 2003 to be 83.6 and 74.6%, respectively, for living donor recipients, compared with 75.9 and 60.3%, respectively, for deceased donor recipients [7 ] . One-year acute rejection rates for the 1999-2003 NAPRTCS cohort are also slightly lower in living, compared with deceased donor recipients (24.8% vs. 28.8%) [7 ] . Living related kidney donation in young children is also associated with improved linear growth after transplantation. A 2006 study compared factors related to posttransplant growth such as donor type, donor age, rejection, time on dialysis, age at transplantation, immunosuppression, and glomerular filtration rate between 72 pediatric living related donor recipients and 145 deceased donor recipients [8 ] . No child received growth hormone therapy. By multivariate analysis, height at 5 years posttransplant was only influenced by donor type, was independent of glomerular filtration rate, and was significantly higher in living related donor recipients (P ¼ 0.04).
Immunosuppression
The development of immunosuppressive protocols that will be safe and effective without an increased risk of rejection remains a challenge to successful pediatric kidney transplantation.
Steroid avoidance/withdrawal
Linear growth is markedly diminished in children with chronic kidney disease because of resistance to endogenous growth hormone as well as nutritional and metabolic factors, and decreased kidney function [9] . Although short stature improves after 'successful transplantation', final adult height is not reached in the majority of the children, largely related to steroid use [10] [11] [12] . In 2005, Vidhun et al. [13] reviewed the Stanford experience with steroid avoidance in pediatric kidney transplantation. The Stanford protocol uses 6 months of therapy with the monoclonal interleukin (IL)-2 receptor antagonist daclizumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil. Fifty-seven patients who received kidney transplants using this protocol have been followed for a mean of 20 AE 10.4 months. Seven (12.3%) patients withdrew from the study and one (1.8%) patient died of sepsis with a functioning graft. The incidence of clinical acute rejection was 8%, and the incidence of subclinical acute rejection 7%. Evidence of tacrolimus toxicity (defined as medial hyalinosis, striped fibrosis, glomerulosclerosis) was present on the 1-year protocol biopsy in 50% of patients. At 1-year posttransplant, creatinine clearance and linear growth were significantly improved, and the incidence of hypertension was significantly decreased in patients on the steroid-free protocol compared with historical controls [13] . The Stanford results are very encouraging and suggest that steroid-free protocols may result in similar patient and graft survival outcomes as those achieved using steroid-based protocols.
Another recent approach combines steroid avoidance and also limits calcineurin inhibitor exposure [14, 15] . The strategy is to employ potent T lymphocyte-depleting agents, such as antithymocyte globulin or alemtuzumab (Campath-1H, an anti-CD52 monoclonal antibody), administered at the time of transplantation. This strategy permits delayed use and lower dosages of calcineurin inhibitors starting at transplantation. It is further hypothesized that in the setting of prolonged lymphocyte depletion afforded by such preconditioning agents, the use of lower maintenance calcineurin immunosuppression shortly after transplantation may enable the coexistence between recipient and donor leukocyte subpopulations, including modification in function of dendritic cells, which may play a crucial role in establishing longterm partial tolerance [15] [16] [17] . An effective protocol in adults undergoing kidney transplantation was then adopted in children and resulted in very encouraging preliminary results [13, 18] . With a mean follow-up time of 1.33 years, 34 unselected children managed by this simple maintenance tacrolimus monotherapy regimen had a low rate of ACR (9%), 100% 1-year allograft survival, and excellent kidney function. There was an acceptable rate of complications and no body disfigurement. Linear growth was outstanding, and medical adherence appeared very high.
Calcineurin inhibitor avoidance
Harmon et al. [19 ] reported the results of a pilot trial of calcineurin inhibitor avoidance in pediatric kidney transplant patients. Thirty-four patients were enrolled in this multicenter trial between February 2001 and August 2003. Immunosuppression included induction with the IL-2 receptor antagonist daclizumab and maintenance immunosuppression with prednisone, sirolimus and mycophenolate mofetil. The mean period of follow-up was 2.1 years. There were no instances of delayed graft function and there were no patient deaths. One patient did not receive a transplant because of a problem with the donor and 13 (38%) patients did not complete the study. At 1-year after transplant, the incidence of acute rejection was 32% and the incidence of posttransplant lymphoproliferative disorder was 6%. Two (6%) grafts were lost, one to acute rejection and posttransplant lymphoproliferative disorder, and one to chronic allograft nephropathy. There were 305 adverse events, 110 (36%) of which were thought to be related to the therapy. Adverse events included infection, vascular disorders, gastrointestinal disorders, neutropenia, anemia, lymphoceles, poor wound healing, and proteinuria lasting more than 1 month. All patients (100%) developed dyslipidemia. Twenty (59%) patients remained on the protocol at follow-up. These early results do not appear to offer improved outcomes compared with those obtained with conventional pediatric immunosuppressive protocols.
Sirolimus
Sirolimus or rapamycin is a macrocyclic lactone immunosuppressive agent that inhibits T lymphocyte activation and proliferation in response to antigens and cytokines [20 ] . It binds to the immunophilin, FK binding protein-12, and forms a complex that binds to and inhibits the activation of the regulatory kinase, mammalian target of rapamycin. It has been used sparingly as maintenance immunosuppression in pediatric kidney transplantation. The 2006 NAPRTCS annual report states that 7.5% of 174 children transplanted in 2005 were receiving sirolimus at day 30 after transplantation [1].
Hymes et al. reported their 6-month experience using sirolimus as maintenance immunosuppression in 66 pediatric kidney transplant patients transplanted between July 2000 and January 2004 [21] . The immunosuppression protocol included induction therapy with the monoclonal IL-2 receptor antagonist basiliximab and maintenance immunosuppression with sirolimus, corticosteroid and tacrolimus or cyclosporine. Patient and graft survival rates at 6 months posttransplant were 100 and 98%, respectively. Biopsy-proven acute rejection occurred in 11% of patients. Dyslipidemia developed in 50% of patients and infection in 14%. Three (60%) of the five patients who developed infection with the Epstein-Barr virus developed posttransplant lymphoproliferative disorder. Sirolimus was withdrawn from 20% of the patients because of adverse events. Adverse events included poor wound healing, pneumonitis, acute rejection, insulin-dependent diabetes mellitus, posttransplant lymphoproliferative disorder, arthralgia, and vomiting [21] . Another possible side effect of sirolimus use is vasculitis. An 18-year-old female patient reportedly developed posttransplant leukocytoclastic vasculitis of the gastrointestinal tract in association with the use of sirolimus immunosuppression [22] . The vasculitis resolved after sirolimus was discontinued and replaced with a low dose of mycophenolate mofetil.
A small, single center study from Germany evaluated the efficacy and safety of switching pediatric kidney transplant recipients with biopsy-proven calcineurin inhibitor nephrotoxicity (arteriolar hyaline deposits and the presence of striped interstitial fibrosis and/or tubular calcifications) to a sirolimus-based immunosuppression protocol (n ¼ 10) vs. calcineurin inhibitor minimization protocol (n ¼ 9) [23] . Patients were excluded if their glomerular filtration rate was less than 35 ml/min/1.73 m 2 , if proteinuria exceeded 1.0 g/m 2 /day, if they had hyperlipidemia, or if there was acute rejection on biopsy at the time of study entry. Both of the immunosuppressive protocols included maintenance immunosuppression with mycophenolate mofetil and corticosteroids. In the calcineurin inhibitor minimization group the calcineurin inhibitor was reduced by a mean of 39%. At 1 year after study entry there was similar improvement or stabilization in glomerular filtration rates in both treatment groups, and the incidence of hypertension and infection was similar between the groups. Proteinuria increased in three of five patients treated with sirolimus who had preexisting proteinuria but there were no cases of de novo proteinuria in either group. At 1 year after the study 70% of the sirolimus treated patients had hyperlipidemia compared with 11% in the minimization group. The authors concluded that the use of either conversion protocol was associated with an improvement in glomerular filtration rate at 12 months after conversion. Prospective studies of the efficacy and safety of sirolimus in pediatric kidney transplant patients are warranted.
Posttransplant infection
Posttransplantation infection is a major cause of mortality and morbidity in pediatric kidney transplant patients [24, 25] . Two recent studies used Medicare claims data submitted to the United States Renal Data System (USRDS) database to compare infection rates in pediatric vs. adult kidney transplant recipients [26 ,27 ] . The study by Dharnidharka et al. [26 ] analyzed the relative risk, frequency trends, and infection profiles (both outpatient and inpatient) during the first year posttransplantation for patients <18 years old (n ¼ 1717), 18-50 years old (n ¼ 37 033), and >51 years old (n ¼ 21 397) who received a kidney transplant between January 1991 and December 1998. All documented infections after transplantation were included in the analysis. The study found, for all groups, a trend towards an increased frequency of first year infections from 1991 to 1998 with a slight decline in frequency in 1998. Patients transplanted after 1995 had a 34% higher risk for infection compared with those transplanted before 1995. Adults >51 years of age had the highest frequency of infection compared with other age groups. In pediatric kidney transplant recipients, the frequency of first-year posttransplant infections increased from about 42% in 1991 to about 50% in 1998. Children experienced more viral and bacterial infections compared with adults and were more likely to be hospitalized. Chavers et al. [27 ] used Medicare claims data submitted to the USRDS database to analyze the incidence of infection-related hospitalizations within 3 years of transplantation in pediatric (age <20 years) and adult dialysis and transplant patients from 1996 to 2001. Infections were included in the study only if the infection was the primary diagnosis at discharge from the hospital setting. The study included 32 771 kidney transplant patients (n ¼ 1108 pediatric, 31 663 adult). The cumulative incidence of infection-related hospitalizations at 3 years posttransplant was higher for pediatric kidney transplant patients compared with adult kidney transplant patients (47.7 vs. 39.8%). Among pediatric end-stage kidney disease patients, infection-related hospitalization rates were highest for kidney transplant patients compared with hemodialysis and peritoneal dialysis patients (P < 0.001 for each comparison). This study emphasizes that in pediatric kidney transplant patients the risk for infection and infection-related hospitalization continues well beyond the first year after transplantation and that they require long-term surveillance for infection after transplantation.
Nonadherence with immunosuppression
Long-term graft survival rates are worse in adolescent (aged 11-19 years) than in younger aged pediatric kidney transplant patients [28] . Dobbels et al. [28] suggest nonadherence with the immunosuppressive regimen is a factor leading to worse long-term graft survival in adolescent kidney transplant patients. Using online databases (Pubmed, Cinahl and Psychlit) and by screening for articles written between 1980 and 2004 on pediatric compliance and/or noncompliance, and nonadherence, they found 12 papers pertaining to pediatric kidney transplant recipients. The number of patients per study ranged from seven to 92. Methods used to define nonadherence included pill counts, self-report or interview, electronic monitoring of pill bottle caps, chart reviews of clinical and/ or behavioral issues, and monitoring of immunosuppressive drug levels. None of the studies determined the level of nonadherence that was associated with a poor transplant outcome. The prevalence of nonadherence ranged from 5 to 71%, and was dependent upon patient number and the method used to define nonadherence. Nonadherence, however, was persistently higher in the adolescent age group compared with the younger age group. Nonadherence was a risk factor for graft loss in 14.1% of the pediatric kidney transplant patients (based on six studies).
Feinstein et al. [29] evaluated the prevalence of noncompliance in 79 pediatric primary kidney transplant recipients. Patients ranged in age from 1.7 to 23 years (mean age 13.6 AE 4.8 years), 59% (n ¼ 47) were adolescents, and the mean period of follow up was 4.8 AE 2.7 years (range 1-13). Noncompliance was defined as discontinuation of one or more immunosuppressive medications, deviation from the prescribed medication regimen, subtherapeutic cyclosporine or tacrolimus levels, and patient self report. The incidence of noncompliance was 16%, and all but one of the noncompliant patients was older than 12 years of age [29] . The authors found that noncompliance was higher in adolescents who received deceased donor kidneys than in those who received living donor kidneys (45.5 vs. 28.6%, respectively; P < 0.01). Acute rejection developed in 69% of the noncompliant patients. All of the patients who developed acute rejection went on to develop chronic allograft nephropathy, and 23% of the noncompliant patients lost their grafts.
Conclusion
Publications in the past 2 years provide support for the use of living donors in pediatric kidney transplant patients (better graft survival rates and improved linear growth) and for more studies of steroid avoidance protocols (improved linear growth, less hypertension without increased risk for rejection). More experience is needed with the use of medications, such as sirolimus, that have a high incidence of adverse effects. Nonadherence is a risk factor for rejection, particularly in adolescent kidney transplant patients. These studies suggest that prospective trials of immunosuppression, adherence, and transplant outcomes continue to be needed in pediatric kidney transplant patients. A trial of calcineurin inhibitor avoidance in pediatric kidney transplant patients. The results emphasize the need for a prospective, randomized trial of sirolimus based immunosuppression in pediatric patients. It also points out the high incidence of adverse events associated with the use of sirolimus immunosuppression in pediatric kidney transplant patients.
